Abstract: The invention relates to a process of treating a plant which applies an agricultural composition which contains Si clay granules or powders and a base wherein the composition is applied in an amount from about 150 pounds to about 4,000 pounds per acre. The invention also relates to an agricultural composition containing Si clay granules or powders and a base wherein the composition can be applied in an amount from about 150 pounds to about 4,000 pounds per acre.

Abstract: The present invention utilizes a high-speed intensive mixer in a fluidizing-type, solid-phase, neutralization reactor to blend solid-state alkali hydroxide with any humic acid sources. The final product is a dry humic acid salt. The purpose of this innovative method is to eliminate a series of complicated unit operations commonly employed by the traditional process. These removed steps may include dissolving caustic soda, mixing in a paste-like formation, extrusion, granulation, drying, and grinding, etc. The invention contributes to a simplified flowsheet, resulting in sharply reduced equipment investment, plant space, and labor and energy costs. All of these factors coupled with increased productivity will drastically lower the overall production cost. Also, the reduction of dust pollution will greatly minimize the impact in environmental protection and safety issues.

Abstract: Provided herein are enantioselective organocatalytic methods for preparing chiral tetraaryl methanes.

Abstract: Disclosed is a production system for methane, including a reaction vessel having a solid electrolyte membrane and an electrode group including at least a pair of electrodes arranged on the solid electrolyte membrane, in which one of the electrodes functions as a cathode side electrode, and the other electrode functions as an anode side electrode, and the one electrode that functions as the cathode side electrode includes a hydrogenation catalyst.

Abstract: A process comprising a heterogeneous reaction between a solid metal organic framework supported sulfonic acid and a hydrocarbon feed to form a modified hydrocarbon stream. The modified hydrocarbon stream comprises essentially of C6+ hydrocarbons.

Abstract: A process comprising a heterogeneous reaction between a solid oxyanion-modified metal organic framework and a hydrocarbon feed to form a modified hydrocarbon stream. The modified hydrocarbon stream comprises essentially of C6+ hydrocarbons.

Abstract: A process comprising a heterogeneous reaction between a solid oxyanion-modified metal organic framework and a hydrocarbon feed to form a modified hydrocarbon stream. The modified hydrocarbon stream comprises essentially of C6+ hydrocarbons.

Abstract: A radio access network (RAN) configured to support real-time communications over a Long-Term Evolution (LTE) connection is described herein. When a request for a data transmission is received and a real-time communication session over the LTE connection is established, the RAN utilizes the LTE connection, not a New Radio (NR) connection, for the data transmission. When a request for a further real-time communication is received and there is an active data transmission session over the NR connection, the RAN performs at least one of ceasing to allocate traffic to the NR connection for downlink or reconfiguring the data transmission session to send data over the LTE connection.

Abstract: A method of producing trifluoroiodomethane (CF3I) includes providing a feedstock comprising trifluoroacetyl iodide (TFAI), passing the feedstock through at least one column charged with carbonaceous materials to remove hydrogen iodide (HI), hydrogen triiodide (HI3) and iodine (I2) from the feedstock, and providing the feedstock to a reactor to produce a trifluoroiodomethane product stream. Another method of producing trifluoroiodomethane (CF3I) includes providing a feedstock comprising trifluoroacetyl iodide (TFAI) to a reactor to produce a trifluoroiodomethane product stream, and passing the trifluoroiodomethane product stream from the reactor through at least one column charged with carbonaceous materials to remove hydrogen iodide (HI), hydrogen triiodide (HI3) and iodine (I2) from the trifluoroiodomethane product stream.

Abstract: A composition including at least 98 mol % of (E/Z)-1-chloro-3,3,3-trifluoropropene and less than 0.5 mol % of coproducts selected from 1,3,3,3-tetrafluoropropene and 1,1,1,3,3-pentafluoropropane. A composition obtained from a process for producing 1-chloro-3,3,3-trifluoropropene, including the step i) of contacting hydrofluoric acid (HF) in a reactor with a starting composition including at least one of the chloro compounds selected from 1,1,3,3-tetrachloropropene (1230za), 1,3,3,3-tetrachloropropene (1230zd) and 1,1,1,3,3-pentachloropropane (240fa), or a mixture thereof, to produce a stream A including 1-chloro-3,3,3-trifluoropropene (1233zd), wherein the step i) is carried out in a low-HF liquid phase.

Abstract: The dehydration membrane reactor for methanol production from CO2 hydrogenation includes one or more porous supports, a dehydration membrane on the one or more porous supports, and a catalyst layer on the dehydration membrane. The one or more porous supports include hollow ceramic fibers and the dehydration membrane includes NaA zeolite. The reactor is made by dip-coating the porous supports in a zeolite crystal seed solution and drying the coated porous support. The coated porous support is dried at about 80° C. and then heated to a temperature above about 200° C. The NaA zeolite membrane is then grown on the seeded support, and a catalyst layer is applied to the zeolite membrane. A feedstream including carbon dioxide and hydrogen is fed to the catalyst layer, where a product stream including methanol and water is evolved. The water is then removed from the product stream through the dehydration membrane to produce a high-purity methanol product.

Abstract: Disclosed herein is a method for obtaining compounds and compositions from plant and fungus materials by thermal treatment, affinity capture, filtration, and release through multi-phasic transitions between gas, solid, and liquid states. The compounds of interest are obtained by manipulating the temperature and pressure of the heating chamber. The compounds in gas phase are passed through an affinity medium which captures the compounds of interest in either solid or liquid phase by exposing the compound of interest to the localized micro-affinity environment of the medium. The compounds are separated from the medium using direct competition with solvent or buffers optimized for the specific chemical properties of compounds.

Abstract: A preparation method for polyoxymethylene dimethyl ether (DMMn, generally, n=3-8 or 2-8) and mixture thereof may include one or more of the following: mixture of aqueous formaldehyde solution and polyalcohol is heated and dehydrated under vacuum conditions to yield flowing polyoxymethylene containing low moisture, which is heated and gasified to obtain relatively pure gaseous formaldehyde, which is mixed with methylal, previous batch of low-boiling-point substances applied, macromolecules, etc. in presence of catalyst. Or, the method mainly includes: aqueous formaldehyde solution, polyalcohol, and previous batch of macromolecular mixture applied are heated under vacuum conditions to remove moisture so as to obtain anhydrous flowable polyoxymethylene etherate, which is mixed with methylal, previous batch of low-boiling-point substances applied, macromolecules, etc. in presence of catalyst.

Abstract: A drug design method associated with natural products, includes: acquiring a molecular structure of a to-be-modified natural product with a specific biological activity; using the molecular structure as a template molecule, selecting a plurality of natural products as a reference molecule set, where the plurality of natural products has the specific biological activity and a structural similarity thereof to the template molecule is within a threshold range; and selecting one or more reference molecules from the reference molecule set, comparing the one or more reference molecules with the template molecule and determining at least one different active functional group therebetween; and constructing the at least one different active functional group on a molecular scaffold shared by the template molecule and the one or more reference molecules, thereby obtaining a modified molecular structure of the natural product with the specific biological activity.

Abstract: A process for producing acetic acid includes: (a) reacting, via a catalytic partial oxidation (CPO) reaction, a CPO reactant mixture in a CPO reactor to produce a hydrogen-lean syngas; wherein the hydrocarbons include equal to or greater than about 3 mol % C2+ alkanes; wherein the hydrogen-lean syngas includes hydrogen, carbon monoxide, carbon dioxide, and unreacted hydrocarbons; and wherein the hydrogen-lean syngas is characterized by a hydrogen to carbon monoxide (H2/CO) molar ratio of from about 0.7 to about 1.3. Also included is (b) feeding at least a portion of the hydrogen-lean syngas and dimethyl ether (DME) to a DME carbonylation unit to produce methyl acetate and a hydrogen-enriched syngas characterized by a H2/CO molar ratio of from about 1.8 to about 2.2; and (c) feeding at least a portion of the methyl acetate and water to a methyl acetate hydrolysis reaction zone to produce acetic acid and a methanol stream.

Abstract: A method forming a blocked 1,1-dicarbonyl substituted comprises reacting an alkene of a 1,1-dicarbonyl substituted alkene with a blocking Michael addition donor compound such as an alcohol or thiol. The blocked 1,1-dicarbonyl substituted alkene may be polymerized by providing sufficient thermal energy whereby at least portion of the blocked alkenes revert to alkenes and may be addition polymerized or Michael added with a multifunctional Michael addition donor compound (e.g., polyol or polythiol).

Abstract: Novel salicylamine derivatives are targeted directly to the mitochondria to increase effectiveness and lower required dosages in the treatment of conditions caused by inflammation or oxidative stress.

Abstract: Aspects of the present invention are directed to structurally modified opioids (SMOs) that result in improved modulating activity at the NMDAR and improved PK and PD parameters over existing drugs with NMDAR modulating activity. The structural modifications of an opioid or opioid enantiomer that result in the SMOs can be obtained by starting the synthetic process de novo; by modifying the synthetic process for the opioid at any intermediate step during the synthesis of the racemate or of one enantiomer; or by modifying the structure of the opioid or opioid enantiomer after the synthesis. The nitric acid ester substitutions are of particular relevance, especially when associated to deuterated substitutions and/or halogen substitutions.

Abstract: The invention relates to a process for preparing N-methyl(meth)acrylamide and to the uses thereof.

Abstract: The present invention relates to a composition for producing an N-vinylcarboxylic acid amide, the composition including (A) an N-(1-alkoxyethyl)carboxylic acid amide and (B) a carboxylic acid amide other than the N-(1-alkoxyethyl)carboxylic acid amide and the N-vinylcarboxylic acid amide, and satisfying the following conditions (1) to (4): (1) the composition has a melting point of 0 to 30° C.; (2) a water content is 0 to 1.00% by mass in a total amount of the composition; (3) a content ratio of the component (A) to the component (B) is 4.0 to 20.0 in terms of a molar ratio; and (4) a 5% by mass aqueous solution of the composition has a pH of 4.0 to 8.0. The present invention also relates to a method for producing an N-vinylcarboxylic acid amide, the method including thermally decomposing or catalytically decomposing the composition for producing an N-vinylcarboxylic acid amide.

Abstract: The present specification relates to an adamantanecarboxylic acid benzyl amide derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, and a skin whitening composition comprising the same as an active ingredient. Specifically, the compound, according to the present specification, is a compound having a novel structure having adamantanecarboxylic acid bound to an amine compound, and exhibits a skin whitening effect by inhibiting the production of melanin, and thus may be used in various ways as a pharmaceutical composition, a cosmetic composition or a skin preparation for external use.

Abstract: Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

Abstract: Provided herein are compounds, compositions and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene carboxamides and protein (e.g., antibody) drug conjugates thereof.

Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Abstract: This patent document discloses novel compounds and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds. As direct inhibitors of Keap1-Nrf2 interaction, the compounds disclosed herein are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential dmg candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, Parkinson's, and inflammatory bowel disease including ulcerative colitis.

Abstract: The anthocyanin synthesized from date palm may include co-pigmented anthocyanin complexes synthesized by extracting an anthocyanin from date palm leaves and reacting the anthocyanin with phenolic compounds also resulting from date palm leaf extraction in order to produce a co-pigmented anthocyanin complex. Date palm leaf powder may be mixed with water containing about 1.08% hydrochloric acid in a glass or ceramic lined reactor, and extraction may be performed by boiling the mixture for an hour or more. The color of the co-pigmented anthocyanin complex produced by this method may be adjusted by continuing the heating in half hour increments, in order to deepen the hue of the co-pigmented anthocyanin complex. The co-pigmented anthocyanin complex may be separated from the liquid mixture by first filtering the liquid mixture, refining the liquid mixture by adding gelatin to form a colloidal solution, and freeze-drying the refined liquid mixture.

Abstract: The disclosure relates to a compound of formula (I): This disclosure also relates to a compound for formula (II): This disclosure also relates to a compound of formula (III): The disclosure also relates to crystalline compounds of formula (I), (II), or (III). The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I), (II), or (III) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I), (II), or (III) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I), (II), or (III).

Abstract: A heterocyclic compound is represented by Formula 1 in the present specification and satisfies at least one of Condition 1 to Condition 5, a light-emitting device includes the heterocyclic compound, and an electronic apparatus includes the light-emitting device. The light-emitting device includes: a first electrode; a second electrode facing the first electrode; and interlayer between the first electrode and the second electrode and including an emission layer; and the heterocyclic compound.

Abstract: Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.

Abstract: Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

Abstract: The compounds of Formula I described herein regulate activity of JAK2 by specifically binding to the JAK2 pseudokinase domain, JH2, and are useful as therapeutic agents in the treatment or amelioration of myeloproliferative disorders. Also provided herein are methods of treating myeloproliferative disorders, and methods of making compounds of Formula I.

Abstract: The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of the following Formula 1a with improved selectivity: wherein R1 and R2 are the same as defined herein.

Abstract: N-substituted formyl-alpha-substituted glycine ester is used as the initial raw material, a cyclization reaction is performed under the action of a dehydrating agent (trisubstituted phosphine dihalide, a combination of trisubstituted phosphine dihalide and an acyl halide reagent, or a combination of trisubstituted phosphine oxide and an acyl halide reagent) and an organic amine to obtain the substituted oxazole compound, and the resulting substituted oxazole compound can be further saponified and de-carboxylated to obtain a medical intermediate 4-substituent-5-substituent oxy-oxazole; the reaction process can be carried out in a continuous flow mode to improve the productivity and reduce operations; the byproduct trisubstituted phosphine oxide in the reaction process can be repeatedly used to reduce the cost; dehydrating agents (phosphorus oxychloride and phosphorus pentoxide).

Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: The inventive subject matter provides compounds, compositions and methods for lowering serum acid (sUA) for the treatment of gout, and having reduced liver toxicity, associated with CYP2C9 metabolic pathway.

Abstract: The invention provides a process for producing diol, characterized in that the process comprises the steps of (1-i) addition of alkylene oxide and carbon dioxide to an H-functional starter substance in the presence of a catalyst to obtain polyether carbonate polyol and cyclic carbonate, (1-ii) separation of the cyclic carbonate from the resulting reaction mixture from step (1-i), (1-iii) hydrolytic cleavage of the cyclic carbonate separated from step (1-ii) into carbon dioxide and diol, (1-iv) optionally distillative purification of the diol from step (1-iii), wherein (?) to the cyclic carbonate from step (1-ii) and/or to the diol a Lewis or Brønsted acid, excluding carboxylic acids having a pKa of >3.0, and optionally water are added and the reaction mixture obtained is optionally neutralized.

Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.

Abstract: Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

Abstract: The present disclosure relates generally to compounds useful for the treatment and/or enhancement of cognitive function and negative symptoms associated with central nervous system disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.

Abstract: A ketoamide compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically, the ketoamide compound shown in formula (A), a racemate, an enantiomer, or a diastereoisomer thereof, or any mixture of same, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof. The ketoamide compound can effectively inhibit coronavirus or Ebola virus, and thereby implement the prevention or treatment of diseases related to coronavirus or diseases related to Ebola virus.

Abstract: RAS modulating compounds and methods of using the same are provided. The subject compounds comprise a core fused bicyclic group based on a quinoline-type scaffold having two fused six-membered aryl or heteroaryl rings, linked to a cyclic group (A) through the 2-position via a linker. The linked cyclic group can be an optionally substituted cyclopentyl or pyrrolidine group. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.

Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.

Abstract: The subject invention pertains to compositions and methods for treating neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis, epilepsy, stroke, alcohol withdrawal, progressive supranuclear palsy (PSP), Pick's disease (PiD), corticobasal degeneration (CBD), frontotemporal dementia or parkinsonism linked to chromosome 17 (FTDP-17). The methods of the subject invention further relate to methods of fermentation of bacterial cells and methods of tautomerization of the subject compounds.

Abstract: Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

Abstract: Invented are compounds of Formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

Abstract: The invention describes a process for reworking of a crystallization product comprising drying and homogenization. The crystallization product is crystalline [5-(methylsulfonyl)-2-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-[5-(trifluoromethyl)-1,2-oxazol-3-yl]-3-azabicyclo[3.1.0]hex-3-yl}methanone. The product is dried in a tray dryer or in a pan dryer and subsequently homogenized.

Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: Compounds of Formula (I), racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions containing the compounds, racemates, enantiomers, diastereomers thereof, and a manufacturing method thereof are disclosed. These compounds have GPR40 agonist activity and are capable of modulating blood glucose levels and glucose-dependent insulin secretion mechanism, and, thus, exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. These compounds could be used in preventing and/or treating type 2 diabetes through adequate control of blood glucose.